The Medicines Company (MDCO) : Zacks Investment Research ranks The Medicines Company (MDCO) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. The average broker rating of 7 research analysts is 1.14, which indicates as a Strong Buy.
The Medicines Company (MDCO) : The consensus price target for The Medicines Company (MDCO) is $50.67 for the short term with a standard deviation of $8.07. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $65, however, the pessimist price target for the company is $43.
For the current week, the company shares have a recommendation consensus of Buy.
The Medicines Company (NASDAQ:MDCO): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $36.57 and $36.09 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $37.07. The buying momentum continued till the end and the stock did not give up its gains. It closed at $36.62, notching a gain of 1.19% for the day. The total traded volume was 1,249,872 . The stock had closed at $36.19 on the previous day.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.